**ABT-263 (Navitoclax)**

**Cat. No.:** A3007  
**CAS No.:** 923564-51-6  
**Formula:** C47H55ClF3N5O6S3  
**M.Wt.:** 974.61  
**Synonyms:** Navitoclax, ABT-263, ABT263, ABT 263  
**Target:** Apoptosis  
**Pathway:** Bcl-2 Family  
**Storage:** Desiccate at -20°C

---

**Solvent & Solubility**

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent</th>
<th>Mass</th>
<th>1mg</th>
<th>5mg</th>
<th>10mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Concentration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 mM</td>
<td>1.0261 mL</td>
<td>5.1303 mL</td>
<td>10.2605 mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5 mM</td>
<td>0.2052 mL</td>
<td>1.0261 mL</td>
<td>2.0521 mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10 mM</td>
<td>0.1026 mL</td>
<td>0.5130 mL</td>
<td>1.0261 mL</td>
<td></td>
</tr>
</tbody>
</table>

≥48.73 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O

Please refer to the solubility information to select the appropriate solvent.

---

**Biological Activity**

**Shortsummary**

Potent Bcl-2 family inhibitor, inhibits Bcl-2, Bcl-xL, and Bcl-w

**IC₅₀ & Target**

≤ 0.5 nM (Kᵢ) (Bcl-xL), ≤ 1 nM (Kᵢ) (Bcl-2), ≤ 1 nM (Kᵢ) (Bcl-w)

**Cell Viability Assay**

**Cell Line:** Murine DO11.10 T-hybridoma cells expressing murine Bcl-2, Bcl-xL and Bcl-w proteins

**Preparation method:** The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions: None specific suggestion

Applications: ABT-263 is an antitumor effector in preclinical and early clinical studies. It binds to Bcl-2, Bcl-xL, and Bcl-w in vitro, but only targets Bcl-2 in vivo. In human non-Hodgkin lymphomas, high expression of Bcl-2 sensitized to ABT-263 elevated proapoptotic Bim.

Animal experiment

Animal models: Immune-deficient NOD/SCID or NOD/SCID ILγ receptor negative mice

Dosage form: Orally taken at 100 mg/kg/day for 21 days

Applications: ABT-263 can largely inhibited the activity of patient-derived pediatric acute lymphoblastic leukemia xenograft. ABT-263 sensitivity was correlated with low MCL1 mRNA expression levels. BH3 profiling revealed that resistance to ABT-263 correlated with mitochondrial priming by NOXA peptide.

Other notes: Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

---

**Product Citations**


---

**References**

1. Mérino D1, Khaw SL, Glaser SP et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.Blood. 2012 Jun 14;119(24):5807-16.

FOR RESEARCH PURPOSES ONLY.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.